Context Therapeutics (CNTX) Projected to Post Quarterly Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts expect Context Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Context Therapeutics Trading Down 4.2%

Shares of NASDAQ:CNTX opened at $0.68 on Tuesday. The company has a 50 day moving average of $0.68 and a 200-day moving average of $0.76. The firm has a market cap of $61.00 million, a P/E ratio of -2.19 and a beta of 1.89. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.75.

Insider Buying and Selling at Context Therapeutics

In other news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $25,606.40. Following the purchase, the chief financial officer owned 80,010 shares of the company’s stock, valued at $51,206.40. This represents a 100.03% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martin A. Lehr bought 100,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was purchased at an average price of $0.70 per share, for a total transaction of $70,000.00. Following the completion of the purchase, the chief executive officer directly owned 920,190 shares in the company, valued at $644,133. The trade was a 12.19% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 160,010 shares of company stock worth $107,206. 3.04% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Piper Sandler reissued an “overweight” rating and set a $4.00 target price (down from $4.50) on shares of Context Therapeutics in a research note on Thursday, June 26th. William Blair reissued an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $5.50.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.